Comparable Outcomes of Pre- Versus Post-Tyrosine Kinase Inhibitor Era Treatment in Chronic Myeloid Leukemia: A Retrospective Cohort Study With Long-term Follow-up

Imatinib, a selective BCR-ABL tyrosine kinase inhibitor (TKI), was introduced after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with chronic myeloid leukemia (CML). However, the long-term effects of allo-HSCT in chronic phase CML patients are mostly unknown. We retros...

Descrición completa

Detalles Bibliográficos

Principais autores:	Sahar Tavakoli, Fattaneh Khalaj, Amir Kasaeian, Seyed Ali Mousavi, Amir-Hossein Mousavian, Fatemeh Arabi, Soroush Rad, Shahrbano Rostami, Maryam Barkhordar, Mohammad Biglari, Heydar Ali Mardani-Fard, Hediyeh Alemi, Naghmeh Khavandgar, Hossein Kamranzadeh Fumani, Ghasem Janbabai, Seied Asadollah Mousavi, Ardeshir Ghavamzadeh, Mohammad Vaezi
Formato:	Artigo
Idioma:	Inglês
Publicado:	SAGE Publishing 2023-04-01
Series:	Cell Transplantation
Acceso en liña:	https://doi.org/10.1177/09636897231163212
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!